Study of AVM0703 for severe lung injury in COVID-19 or flu
Part of Infections, Lungs & breathing clinical trials.
This trial tests a drug called AVM0703 to see if it can help people with severe lung damage caused by COVID-19 or influenza. It focuses on patients who need a breathing machine or ECMO because their lungs are failing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed COVID-19 or Influenza (A or B) infection.
- Your lung function must be severely impaired, requiring a breathing tube (intubation) or a heart-lung bypass machine (ECMO).
- You must have a certain level of oxygen in your blood, confirmed by a blood test.
- If you are capable of getting pregnant, you must have a negative pregnancy test and agree to use birth control during the study.
- You or your legal representative must be able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This study tests an investigational stem cell treatment called MesenCure for people with acute respiratory distress syndrome (ARDS), a serious lung condition that often occurs with COVID-19. The treatment may help reduce lung inflammation and improve breathing.
This trial tests an experimental drug called Fluorothiazinone to prevent serious bacterial infections in ICU patients who are on a breathing machine (ventilator) or likely to need one soon. It includes patients with COVID-19 pneumonia, stroke, or heart failure.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
Hear when a new ARDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.